Eosinophilic Disorders Market Report: Global Overview To Reach $278Mn By 2031 | Most Leading Companies - Novartis A.G, GlaxoSmithKline Plc., Teva Pharmaceutical, Pfizer Inc., AstraZeneca

The Global Eosinophilic Disorders Market reached US$ 150 million in 2023 and is expected to reach US$ 278 million by 2031 growing with a CAGR of 7.1% during the forecast period 2024-2031.

Eosinophilic Disorders Market, as detailed in the DataM Intelligence report, presents a strategic overview of the industry backed by in-depth data and market trends. The study highlights the performance and positioning of major players, focusing on their offerings, pricing models, financial outcomes, and growth strategies. It serves as a concise yet insightful reference for understanding the current landscape and future direction of the market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/eosinophilic-disorders-market?kb

Market Overview:

Eosinophilic disorders are a group of medical conditions characterized by an abnormally high number of eosinophils a type of white blood cell in the blood or tissues. Eosinophils play a role in the immune system, especially in allergic reactions and fighting certain infections. When elevated excessively, eosinophils can cause inflammation and damage to organs such as the lungs, skin, gastrointestinal tract, and heart.

Common eosinophilic disorders include eosinophilic asthma, eosinophilic esophagitis, and hypereosinophilic syndrome.

List of the Key Players in the Eosinophilic Disorders Market:

Novartis A.G, GlaxoSmithKline Plc., Teva Pharmaceutical, Pfizer Inc., AstraZeneca, Sanofi S.A, Curia, LGM Pharma, Henan Lihua Pharmaceuticals Ltd., and Hikma Pharmaceuticals among others.

Eosinophilic Disorders Market Development:

In February 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) approved EOHILIA (budesonide oral suspension), marking it as the first and only FDA-approved oral treatment for individuals aged 11 and older with eosinophilic esophagitis (EoE).

Also in February 2024, Phase III data from the MANDARA study, published in the New England Journal of Medicine, demonstrated that remission is an attainable goal in eosinophilic granulomatosis with polyangiitis (EGPA) when treated with FASENRA.

Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/eosinophilic-disorders-market?kb

Segment Covered in the Eosinophilic Disorders Market:

By Type: Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Enteritis, Eosinophilic Colitis, Hypereosinophilic Syndrome

By Treatment: Medications, Dietary Therapy, Dilation, Others

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others

Regional Analysis for Eosinophilic Disorders Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Frequently asked questions:

➠ What are the global sales, production, consumption, import, and export figures for the Eosinophilic Disorders market?

➠ Who are the key global manufacturers, and how are they performing operationally?

➠ What opportunities and risks do vendors face in the Eosinophilic Disorders market?

➠ Which product types or end-users show the most growth potential, and what are their market shares?

➠ What factors are driving or limiting growth in the Eosinophilic Disorders market?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us-

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us-

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.